title: Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review.
abstract: Myelofibrosis is a myeloproliferative neoplasm with cardinal features of extramedullary hematopoiesis, hepatosplenomegaly, cytopenias, and constitutional symptoms that result in shortened survival and leukemic transformation. It is a disease predominantly of the elderly, and currently available therapies only offer symptom control without curative benefit or ability to alter disease progression. Allogeneic hematopoietic stem-cell transplant (HSCT) is the only potentially curative intervention; however, this is only feasible in younger and medically fit patients and selectively offered to those with high-risk disease. Despite ongoing advancements, HSCT is associated with substantial morbidity and mortality, and the determination of which patients with myelofibrosis are ideal candidates and the selection of the opportune moment to proceed with transplantation remains challenging. This review summarizes our current recommendations for the role of and indications for HSCT in myelofibrosis.
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Nosha
authors.initials: N
authors.lastname: Farhadfar
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Sonia
authors.initials: S
authors.lastname: Cerquozzi
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Mrinal
authors.initials: M
authors.lastname: Patnaik
authors.affiliation: Mayo Clinic, Rochester, MN tefferi.ayalew@mayo.edu.
authors.forename: Ayalew
authors.initials: A
authors.lastname: Tefferi
mesh_terms: D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D009154:Mutation; D055728:Primary Myelofibrosis / Q000235:genetics / Q000628:therapy*; D012008:Recurrence; D012307:Risk Factors; D014019:Tissue Donors; D014184:Transplantation, Homologous